Enanta Pharmaceuticals, Inc.

NASDAQ:ENTA

Biotechnology

Healthcare
$8.69 -0.67%

-$0.09 today

Market cap
$253.10M
Beta
0.99
P/E (TTM)
-4.3
EPS (TTM)
-$2.90
52W Low $6.44High $17.15

Volume 0.85M

Average 0.17M

Returns on capital

Enanta Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-126.5%

avg -24.4%

ROIC

-31.4%

avg -8.4%

ROA

-29.2%

avg -6.7%

Analysis

ROA is currently the strongest return metric at -29.2% versus its period average of -6.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Scott T. Rottinghaus

Chief Medical OfficerUSD 863.71K5223.79K0.10%

Yat Sun Or

Chief Scientific OfficerUSD 814.29K74373.04K1.61%

Jay R. Luly

President, Chief Executive Officer & DirectorUSD 742.27K70862.83K3.72%

Nathaniel S. Gardiner

ConsultantUSD 672.68K7275.69K0.33%

Brendan Luu

Chief Business OfficerUSD 622.86K5139.90K0.17%

Matthew Kowalsky

Chief Legal Officer & Corporate SecretaryUSD 575.65K53——

Tara Lynn Kieffer

Chief Operating Officer & Chief Product Strategy OfficerUSD 496.85K4832.20K0.14%

Harry R. Trout

VP of Finance & Interim Principal Financial Officer—57——

Jennifer Viera

Executive Director of Investor Relations & Corporate Communications————

Kathleen S. Capps

Executive Director of Accounting, Controller & Interim Principal Accounting Officer—418.38K0.04%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 8, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

9

$183,166.60

Net Transaction Value

−$183,166.60

Net selling

Most Active

Capps Kathleen S.

2 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Dec 5, 25

Luly Jay R.

Direct

Sell$67.5K
Dec 5, 25

Capps Kathleen S.

Direct

Sell$4.6K
Dec 5, 25

Trout Harry R. III

Direct

Sell$7.7K
Dec 5, 25

Rottinghaus Scott T.

Direct

Sell$11.4K
Dec 5, 25

Luu Brendan

Direct

Sell$19.8K
Dec 5, 25

Kieffer Tara Lynn

Direct

Sell$30K
Dec 5, 25

Or Yat Sun

Direct

Sell$34K
Dec 2, 25

Capps Kathleen S.

Direct

Sell$2.9K
Dec 2, 25

Trout Harry R. III

Direct

Sell$5.3K

Summary

Insiders reported 0 buys worth $0.00 and 9 sells worth $183,166.60 over the last 12 months. That adds up to net selling of $183,166.60. Capps Kathleen S. was the most active insider with 2 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/A-8.8%
+26.4% (6yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Recent growth has been strongest in Revenue at -8.8% over three years. Forward estimates point to Revenue at +26.4% (6yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Enanta Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ENTA's management, answered from reported figures.

Who manages ENTA?

Enanta Pharmaceuticals, Inc. (ENTA) lists 10 active executives. The top listed executive is Scott T. Rottinghaus, Chief Medical Officer.

Are ENTA insiders buying or selling?

Recent insider activity shows net buying of $26.86M.